CD8A and breast carcinoma: In the SweBCG91RT trial, immune infiltrates, in the form of CD8+ T cells and FOXP3+ T cells, were examined in early-stage breast cancer patients that received breast-conserving surgery (BCS) and postoperative radiotherapy.